Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
Healio4d
Lepodisiran lowers Lp(a) substantially with infrequent administration
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Fierce Biotech4d
Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
Opinion
LLY- What Lepodisiran Could Mean for this Big Pharma Play
Lepodisiran is being developed by biotech giant Eli Lilly & Co. (LLY), a stock that’s in my model portfolio. Here’s the tale of this new drug…how it could help millions of heart-ailment sufferers…and ...
BioPharma Dive3d
Lilly study data reinforce potential of new kind of heart drug
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Explore more
Eli Lilly announces Phase 2 trial of lepodisiran met primary endpoint
Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...
Hosted on MSN3d
siRNA Agent Slashes Lipoprotein(a) Levels
CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...